ADAR1 Capital Management, LLC
Reported holdings as of Q2 2026, from 11 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ABIVAX SA OPT | ABVX | $246.4M | 1,804,703 | +1.85pp | 10q | +29.5%+$56.1M | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $117.8M | 960,863 | -0.78pp | 11q | -3.3%-$4.1M | |
| STATE STR SPDR S&P 500 ETF T OPT | SPY | $115.1M | 129,087 | +2.36pp | 5q | +70.0%+$47.4M | |
| ROIVANT SCIENCES LTD | ROIV | $111.7M | 3,157,008 | -0.25pp | 11q | -3.9%-$4.6M | |
| IMMUNOVANT INC | IMVT | $89.8M | 2,330,716 | +0.19pp | 11q | -13.0%-$13.4M | |
| ZAI LAB LTD | ZLAB | $64.0M | 3,369,034 | +1.35pp | 11q | +136.4%+$36.9M | |
| AGIOS PHARMACEUTICALS INC | AGIO | $47.8M | 1,288,053 | +1.91pp | 6q | +815.6%+$42.6M | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $45.7M | 1,222,080 | -0.34pp | 9q | +7.3%+$3.1M | |
| EA SERIES TRUST | BOXX | $39.5M | 337,125 | -0.50pp | 10q | HELD | |
| CYTOKINETICS INC | CYTK | $39.0M | 457,907 | -0.67pp | 11q | -27.6%-$14.9M | |
| SEPTERNA INC | SEPN | $31.5M | 940,747 | -0.10pp | 6q | -13.7%-$5.0M | |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $31.0M | 3,145,096 | +0.18pp | 7q | -17.0%-$6.3M | |
| EDITAS MEDICINE INC | EDIT | $28.8M | 8,889,000 | - | new | NEW | |
| DENALI THERAPEUTICS INC | DNLI | $26.5M | 1,029,080 | -0.90pp | 10q | -45.0%-$21.7M | |
| SPYRE THERAPEUTICS INC | SYRE | $25.2M | 283,982 | +0.15pp | 6q | -16.1%-$4.8M | |
| VIR BIOTECHNOLOGY INC | VIR | $25.0M | 2,456,677 | -0.30pp | 2q | -10.5%-$2.9M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $24.9M | 74,253 | +1.11pp | 3q | +4850.2%+$24.4M | |
| INSMED INC | INSM | $24.4M | 228,520 | +0.77pp | 2q | +545.7%+$20.6M | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $23.1M | 619,542 | +0.26pp | 6q | +44.8%+$7.1M | |
| VIKING THERAPEUTICS INC | VKTX | $22.4M | 574,038 | +0.59pp | 11q | +152.1%+$13.5M | |
| TAYSHA GENE THERAPIES INC | TSHA | $20.7M | 3,040,466 | +0.16pp | 11q | +2.0%+$415.7K | |
| MONOPAR THERAPEUTICS INC | MNPR | $20.1M | 217,595 | +0.07pp | 7q | -17.7%-$4.3M | |
| OVID THERAPEUTICS INC | OVID | $20.0M | 7,417,479 | +0.32pp | 11q | +63.2%+$7.7M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $19.7M | 387,718 | +0.14pp | 3q | +17.7%+$3.0M | |
| ENANTA PHARMACEUTICALS INC | ENTA | $19.6M | 1,344,510 | +0.86pp | 3q | +2518.0%+$18.9M | |
| ISHARES TR OPT | IWM | $18.8M | options only | +0.46pp | 3q | OPTIONS | |
| NEKTAR THERAPEUTICS | NKTR | $17.0M | 244,184 | +0.10pp | 5q | +51.4%+$5.8M | |
| INSPIRE MED SYS INC | INSP | $16.7M | 374,617 | -0.47pp | 4q | -7.5%-$1.4M | |
| REVOLUTION MEDICINES INC | RVMD | $16.4M | 87,509 | -0.02pp | 8q | -34.6%-$8.7M | |
| ESTABLISHMENT LABS HLDGS INC | ESTA | $15.9M | 185,619 | +0.02pp | 6q | -13.0%-$2.4M | |
| PROTHENA CORP PLC | PRTA | $15.2M | 1,554,535 | -0.21pp | 5q | -1.7%-$263.4K | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $15.1M | 136,158 | -0.39pp | 7q | -35.6%-$8.4M | |
| INHIBIKASE THERAPEUTICS INC | IKT | $15.0M | 7,387,205 | +0.03pp | 7q | +11.8%+$1.6M | |
| UNIQURE NV | QURE | $15.0M | 324,672 | +0.51pp | 4q | +326.0%+$11.4M | |
| RALLYBIO CORP | RLYB | $14.8M | 926,352 | +0.67pp | 2q | +4411.1%+$14.5M | |
| REGENERON PHARMACEUTICALS | REGN | $13.8M | 22,208 | +0.08pp | 8q | +82.7%+$6.3M | |
| INVENTIVA SA | IVA | $13.6M | 3,606,656 | -0.09pp | 3q | +65.9%+$5.4M | |
| SUTRO BIOPHARMA INC | STRO | $13.4M | 404,014 | -0.16pp | 3q | -23.0%-$4.0M | |
| IONIS PHARMACEUTICALS INC | IONS | $13.2M | 166,286 | -0.11pp | 5q | +3.7%+$471.6K | |
| BRIDGEBIO PHARMA INC | BBIO | $13.2M | 176,689 | +0.19pp | 11q | +87.4%+$6.1M | |
| SAREPTA THERAPEUTICS INC | SRPT | $13.1M | 730,649 | +0.27pp | 11q | +178.8%+$8.4M | |
| CYTOMX THERAPEUTICS INC | CTMX | $12.6M | 3,365,118 | -0.37pp | 10q | -1.3%-$169.0K | |
| VOR BIOPHARMA INC | VOR | $12.5M | 680,626 | - | new | NEW | |
| SPDR SERIES TRUST | BIL | $12.4M | 135,585 | -0.16pp | 11q | HELD | |
| EQUILLIUM INC | EQ | $12.0M | 3,758,569 | +0.11pp | 4q | +0.9%+$102.1K | |
| ADLAI NORTYE LTD | ANL | $11.7M | 1,017,805 | +0.49pp | 2q | +763.2%+$10.3M | |
| CLIMB BIO INC | CLYM | $10.7M | 822,649 | +0.25pp | 9q | +37.6%+$2.9M | |
| SPDR SERIES TRUST OPT | XBI | $10.7M | options only | +0.38pp | 2q | OPTIONS | |
| HELIX ACQUISITION CORP III | HLXC | $10.6M | 1,000,000 | -0.12pp | 2q | HELD | |
| ZURA BIO LTD | ZURA | $10.4M | 1,759,295 | +0.25pp | 8q | +179.1%+$6.7M | |
| ONKURE THERAPEUTICS INC | OKUR | $10.2M | 2,238,684 | -0.13pp | 3q | -8.1%-$894.9K | |
| MAZE THERAPEUTICS INC | MAZE | $10.1M | 339,276 | +0.38pp | 4q | +577.3%+$8.6M | |
| XENON PHARMACEUTICALS INC | XENE | $10.1M | 166,550 | -0.32pp | 9q | -27.2%-$3.8M | |
| AMYLYX PHARMACEUTICALS INC OPT | AMLX | $9.6M | 494,378 | -0.38pp | 11q | -50.6%-$9.8M | |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | $9.4M | 277,848 | -0.05pp | 11q | +3.5%+$320.4K | |
| UROGEN PHARMA LTD | URGN | $9.3M | 252,395 | +0.01pp | 5q | -36.2%-$5.3M | |
| FAETH THERAPEUTICS INC | FTH | $9.0M | 361,010 | - | new | NEW | |
| DBV TECHNOLOGIES S A | DBVT | $8.7M | 528,295 | -0.85pp | 2q | -47.8%-$7.9M | |
| SAVARA INC | SVRA | $8.6M | 1,403,409 | -0.08pp | 10q | -4.2%-$376.5K | |
| VAXCYTE INC | PCVX | $8.5M | 146,034 | -0.50pp | 6q | -43.6%-$6.6M | |
| CG ONCOLOGY INC | CGON | $8.4M | 118,664 | -0.35pp | 10q | -36.1%-$4.8M | |
| MINERALYS THERAPEUTICS INC | MLYS | $8.1M | 298,886 | +0.12pp | 10q | +93.2%+$3.9M | |
| ASCENDIS PHARMA A/S | ASND | $7.6M | 28,604 | - | new | NEW | |
| AMANAT ACQUISITION CORP | AMAN | $7.6M | 750,000 | - | new | NEW | |
| NURIX THERAPEUTICS INC | NRIX | $7.6M | 313,236 | +0.30pp | 7q | +458.7%+$6.2M | |
| BIOHAVEN LTD | BHVN | $7.5M | 501,687 | +0.32pp | 6q | +1020.4%+$6.8M | |
| PRIME MEDICINE INC | PRME | $7.4M | 1,997,552 | -0.07pp | 2q | +1.2%+$89.6K | |
| PERCEPTIVE CAP SOLUTIONS COR | PCSC | $7.3M | 674,695 | +0.01pp | 9q | +35.1%+$1.9M | |
| OPUS GENETICS INC | IRD | $7.3M | 1,783,781 | -0.16pp | 3q | -3.5%-$268.1K | |
| LEXEO THERAPEUTICS INC | LXEO | $7.3M | 1,565,950 | -0.16pp | 9q | +6.7%+$459.0K | |
| DAMORA THERAPEUTICS INC | DMRA | $7.3M | 280,000 | -0.09pp | 2q | HELD | |
| REPLIMUNE GROUP INC | REPL | $7.3M | 655,784 | -0.43pp | 5q | -58.6%-$10.3M | |
| LEONABIO INC | LONA | $7.1M | 777,100 | -0.11pp | 3q | +6.8%+$456.0K | |
| KORRO BIO INC | KRRO | $7.1M | 540,054 | -0.03pp | 2q | HELD | |
| RESEARCH ALLIANCE CORP III | RACC | $7.0M | 650,000 | - | new | NEW | |
| INFLARX NV | IFRX | $6.7M | 3,000,000 | +0.30pp | 2q | +1795.5%+$6.4M | |
| RELAY THERAPEUTICS INC | RLAY | $6.7M | 358,333 | - | new | NEW | |
| JANUX THERAPEUTICS INC | JANX | $6.5M | 420,881 | +0.05pp | 10q | +41.0%+$1.9M | |
| PLIANT THERAPEUTICS INC | PLRX | $6.3M | 5,509,724 | +0.10pp | 3q | +113.1%+$3.3M | |
| WHITEHAWK THERAPEUTICS INC | WHWK | $6.1M | 1,341,394 | +0.26pp | 3q | +943.9%+$5.6M | |
| KRYSTAL BIOTECH INC | KRYS | $6.1M | 16,420 | -0.03pp | 4q | -18.0%-$1.3M | |
| ARBUTUS BIOPHARMA CORP | ABUS | $6.1M | 1,268,147 | -0.55pp | 11q | -59.5%-$9.0M | |
| PFIZER INC | PFE | $6.1M | 252,400 | +0.15pp | 11q | +226.1%+$4.2M | |
| BRIGHTHOUSE FINL INC | BHF | $6.0M | 95,523 | -0.06pp | 4q | HELD | |
| EDGEWISE THERAPEUTICS INC | EWTX | $5.8M | 143,199 | +0.10pp | 6q | +58.1%+$2.1M | |
| ALECTOR INC | ALEC | $5.8M | 2,883,583 | +0.13pp | 3q | +174.6%+$3.7M | |
| FULCRUM THERAPEUTICS INC | FULC | $5.7M | 1,565,029 | +0.20pp | 11q | +1098.7%+$5.3M | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $5.7M | 69,800 | flat | 11q | -0.7%-$40.8K | |
| ACUMEN PHARMACEUTICALS INC | ABOS | $5.6M | 2,111,334 | -0.04pp | 7q | -2.1%-$120.2K | |
| OAKTREE ACQUISITION CORP III | OACCU | $5.6M | 516,482 | -0.07pp | 7q | HELD | |
| GLOBUS MED INC | GMED | $5.5M | 70,100 | +0.15pp | 3q | +248.8%+$4.0M | |
| MONTE ROSA THERAPEUTICS INC | GLUE | $5.2M | 216,752 | +0.03pp | 4q | HELD | |
| DISCIPLINED GROWTH | $5.0M | 500,000 | - | new | NEW | ||
| BHAV ACQUISITION CORP | BHAVU | $5.0M | 495,000 | -0.06pp | 2q | HELD | |
| BRIDGEBIO PHARMA INC | $5.0M | 30,000 | -0.06pp | 2q | DEBT | ||
| BRIDGEBIO PHARMA INC | $4.9M | 45,000 | -0.06pp | 2q | DEBT | ||
| DANAHER CORP DEL | DHR | $4.9M | 25,932 | -0.12pp | 3q | -16.2%-$952.4K | |
| BOUNDLESS BIO INC | BOLD | $4.9M | 1,968,216 | - | new | NEW | |
| AVALYN PHARMACEUTICALS INC | AVLN | $4.8M | 146,447 | - | new | NEW | |
| ARS PHARMACEUTICALS INC | SPRY | $4.8M | 600,999 | -0.42pp | 4q | -55.9%-$6.1M | |
| ATAIBECKLEY INC | ATAI | $4.8M | 913,242 | +0.03pp | 2q | HELD | |
| PRELUDE THERAPEUTICS INC | PRLD | $4.8M | 900,900 | +0.19pp | 2q | +489.5%+$4.0M | |
| JATT II ACQUISITION CORP | $4.7M | 417,724 | - | new | NEW | ||
| REIN THERAPEUTICS INC | RNTX | $4.7M | 4,500,000 | - | new | NEW | |
| PEPGEN INC | PEPG | $4.7M | 2,591,085 | +0.05pp | 6q | +61.2%+$1.8M | |
| CONTINEUM THERAPEUTICS INC | CTNM | $4.6M | 278,961 | flat | 8q | +0.8%+$37.7K | |
| CORBUS PHARMACEUTICALS HLDGS OPT | CRBP | $4.5M | 421,787 | flat | 4q | +27.1%+$964.4K | |
| PERSPECTIVE THERAPEUTICS INC | CATX | $4.1M | 1,210,117 | flat | 3q | +61.5%+$1.6M | |
| APOGEE THERAPEUTICS INC | APGE | $4.1M | 31,000 | - | new | NEW | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $4.0M | 118,623 | -0.04pp | 5q | HELD | |
| BIOGEN INC | BIIB | $3.9M | 17,900 | +0.06pp | 8q | +62.7%+$1.5M | |
| XENCOR INC | XNCR | $3.7M | 232,560 | +0.10pp | 8q | +148.3%+$2.2M | |
| SILENCE THERAPEUTICS PLC | SLN | $3.7M | 338,373 | +0.12pp | 11q | +96.5%+$1.8M | |
| SPRUCE BIOSCIENCES INC | SPRB | $3.7M | 67,717 | -0.06pp | 3q | +15.6%+$492.3K | |
| PHARVARIS N V | PHVS | $3.6M | 105,528 | -0.01pp | 5q | HELD | |
| Engene Therapeutics Inc | ENGN | $3.6M | 2,104,986 | - | new | NEW | |
| PALISADE BIO INC | PALI | $3.6M | 1,726,662 | -0.07pp | 3q | -23.8%-$1.1M | |
| PROTARA THERAPEUTICS INC | TARA | $3.6M | 940,512 | -0.12pp | 7q | HELD | |
| BRIDGEBIO PHARMA INC | $3.5M | 20,000 | -0.05pp | 2q | DEBT | ||
| SAGIMET BIOSCIENCES INC | SGMT | $3.4M | 437,500 | - | new | NEW | |
| BEONE MEDICINES LTD | ONC | $3.3M | 11,701 | -0.05pp | 2q | HELD | |
| INVIVYD INC | IVVD | $3.3M | 3,807,427 | -0.14pp | 4q | HELD | |
| TENAX THERAPEUTICS INC | TENX | $3.2M | 220,462 | -0.05pp | 8q | +3.3%+$101.8K | |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | $3.2M | 652,750 | +0.12pp | 5q | +351.3%+$2.5M | |
| RELMADA THERAPEUTICS INC | RLMD | $3.1M | 451,918 | -0.04pp | 3q | HELD | |
| DELCATH SYS INC | DCTH | $2.8M | 224,385 | +0.01pp | 11q | HELD | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $2.8M | 49,000 | +0.07pp | 8q | +169.2%+$1.8M | |
| SUMMIT THERAPEUTICS INC | SMMT | $2.8M | 191,869 | +0.03pp | 6q | +108.9%+$1.5M | |
| KEROS THERAPEUTICS INC | KROS | $2.6M | 246,818 | +0.06pp | 11q | +153.6%+$1.6M | |
| ELEDON PHARMACEUTICALS INC | ELDN | $2.6M | 647,812 | -0.06pp | 3q | -33.5%-$1.3M | |
| SANOFI SA | SNY | $2.4M | 57,100 | -0.79pp | 5q | -82.0%-$11.1M | |
| AMERICAN EXCEPTIONALISM ACQU | AEXA | $2.4M | 205,408 | -0.12pp | 4q | -42.5%-$1.8M | |
| TANGO THERAPEUTICS INC | TNGX | $2.4M | 76,761 | +0.05pp | 3q | +53.5%+$836.5K | |
| INTUITIVE SURGICAL INC | ISRG | $2.4M | 6,030 | +0.06pp | 3q | +229.5%+$1.7M | |
| INOVIO PHARMACEUTICALS INC | INO | $2.4M | 2,143,910 | -0.04pp | 3q | +45.8%+$741.2K | |
| OMNIAB INC | OABI | $2.3M | 947,412 | +0.04pp | 11q | +34.3%+$595.9K | |
| CAPRICOR THERAPEUTICS INC | CAPR | $2.2M | 90,593 | -0.06pp | 2q | HELD | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $2.1M | 30,300 | -0.05pp | 3q | -10.6%-$252.7K | |
| ORUKA THERAPEUTICS INC | ORKA | $2.0M | 20,840 | +0.03pp | 6q | HELD | |
| VYNE THERAPEUTICS INC | VYNE | $1.9M | 2,950,000 | +0.05pp | 3q | +177.3%+$1.2M | |
| NOVO-NORDISK A S OPT | NVO | $1.9M | 27,000 | -0.01pp | 2q | -18.2%-$426.1K | |
| MCKESSON CORP | MCK | $1.9M | 2,500 | +0.03pp | 3q | +108.3%+$982.3K | |
| LEXICON PHARMACEUTICALS INC | LXRX | $1.8M | 750,000 | +0.01pp | 2q | HELD | |
| CORVUS PHARMACEUTICALS INC | CRVS | $1.7M | 117,101 | flat | 3q | +33.2%+$436.2K | |
| CUE BIOPHARMA INC | CUE | $1.7M | 55,193 | - | new | NEW | |
| SATELLOS BIOSCIENCE INC | MSLE | $1.7M | 222,555 | +0.01pp | 2q | HELD | |
| KINIKSA PHARMACEUTICALS INTL | KNSA | $1.7M | 26,913 | flat | 9q | HELD | |
| CONNECT BIOPHARMA HLDGS LTD | CNTB | $1.7M | 700,000 | -0.04pp | 2q | -5.7%-$100.9K | |
| COHEN CIRCLE ACQUISIT CORP I | CCIIU | $1.6M | 150,000 | -0.02pp | 4q | HELD | |
| ROCKET PHARMACEUTICALS INC | RCKT | $1.5M | 435,500 | -0.02pp | 9q | +0.7%+$10.3K | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $1.4M | 71,910 | - | new | NEW | |
| EVOMMUNE INC | EVMN | $1.4M | 104,035 | -0.19pp | 3q | -43.5%-$1.1M | |
| C4 THERAPEUTICS INC | CCCC | $1.4M | 291,957 | +0.06pp | 2q | +579.0%+$1.2M | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $1.3M | 133,000 | flat | 3q | +26.7%+$280.0K | |
| SUPERNUS PHARMACEUTICALS | SUPN | $1.3M | 27,842 | -0.03pp | 4q | -6.1%-$83.7K | |
| AVANTOR INC | AVTR | $1.3M | 130,000 | +0.02pp | 5q | +62.5%+$495.0K | |
| INMED PHARMACEUTICALS INC | INM | $1.2M | 800,000 | - | new | NEW | |
| PROMIS NEUROSCIENCES INC | PMN | $1.2M | 92,850 | -0.02pp | 2q | -2.6%-$32.9K | |
| ARROWHEAD PHARMACEUTICALS IN | $1.2M | 10,000 | -0.01pp | 2q | DEBT | ||
| ARTIVA BIOTHERAPEUTICS INC | ARTV | $1.2M | 118,624 | - | new | NEW | |
| TENAYA THERAPEUTICS INC | TNYA | $1.1M | 1,555,500 | -0.01pp | 3q | +3.2%+$35.3K | |
| ALX ONCOLOGY HLDGS INC | ALXO | $1.1M | 533,660 | - | new | NEW | |
| ALEXANDRIA REAL ESTATE EQ IN | ARE | $1.0M | 19,500 | -0.01pp | 3q | HELD | |
| CARTESIAN THERAPEUTICS INC | RNAC | $1.0M | 98,877 | - | new | NEW | |
| CYCLERION THERAPEUTICS INC | CYCN | $1.0M | 298,757 | - | new | NEW | |
| ELECTRONIC ARTS INC | EA | $1.0M | 4,936 | -0.01pp | 4q | HELD | |
| TRAVERE THERAPEUTICS INC | $1.0M | 10,000 | - | new | DEBT | ||
| BIONTECH SE | BNTX | $986.3K | 10,600 | -0.01pp | 4q | +6.0%+$55.8K | |
| ACADIA PHARMACEUTICALS INC | ACAD | $985.6K | 38,955 | - | new | NEW | |
| DYNE THERAPEUTICS INC | DYN | $951.1K | 42,821 | -0.01pp | 6q | -9.8%-$103.1K | |
| MAPLIGHT THERAPEUTICS INC | MPLT | $949.7K | 26,497 | -0.41pp | 2q | -92.9%-$12.5M | |
| STRUCTURE THERAPEUTICS INC | GPCR | $939.2K | 17,500 | - | new | NEW | |
| KEEN VISION ACQUISITION CORP OPT | KVAC | $930.0K | options only | -0.01pp | 5q | OPTIONS | |
| WAVE LIFE SCIENCES LTD | WVE | $929.6K | 160,000 | +0.02pp | 2q | +256.3%+$668.7K | |
| AURA BIOSCIENCES INC | AURA | $924.1K | 130,152 | - | new | NEW | |
| CHURCHILL CAP CORP XI | CCXI | $872.5K | 50,000 | - | new | NEW | |
| KAZIA THERAPEUTICS LTD | KZIA | $866.6K | 61,550 | - | new | NEW | |
| NUVALENT INC | NUVL | $857.3K | 6,942 | flat | 5q | HELD | |
| LARIMAR THERAPEUTICS INC | LRMR | $831.9K | 272,745 | +0.02pp | 5q | +417.1%+$671.0K | |
| VERA THERAPEUTICS INC | VERA | $786.2K | 18,322 | flat | 3q | +14.3%+$98.2K | |
| ADAGIO MED HLDGS INC | ADGM | $785.5K | 1,205,447 | -0.05pp | 3q | HELD | |
| ATRIUM THERAPEUTICS INC | RNA | $775.9K | 57,688 | -0.01pp | 2q | HELD | |
| THERAPEUTICSMD INC | TXMD | $756.8K | 342,447 | +0.01pp | 11q | +63.7%+$294.5K | |
| IDEAYA BIOSCIENCES INC | IDYA | $745.4K | 20,000 | -0.01pp | 4q | HELD | |
| SI-BONE INC | SIBN | $734.4K | 45,000 | +0.02pp | 2q | +257.7%+$529.1K | |
| ROYALTY PHARMA PLC | RPRX | $700.9K | 12,500 | +0.02pp | 2q | +150.0%+$420.5K | |
| EVOLUS INC | EOLS | $694.0K | 100,000 | +0.02pp | 3q | +79.0%+$306.3K | |
| ULTRAGENYX PHARMACEUTICAL IN OPT | RARE | $667.8K | options only | -0.01pp | 4q | OPTIONS | |
| IBIO INC | IBIO | $657.2K | 375,531 | -0.02pp | 5q | -20.1%-$165.1K | |
| FORWARD AIR CORP | FWRD | $651.7K | 48,241 | -0.05pp | 3q | -38.3%-$405.3K | |
| GERON CORP | GERN | $647.4K | 505,817 | +0.01pp | 11q | +152.9%+$391.4K | |
| STRYKER CORPORATION | SYK | $629.7K | 2,000 | - | new | NEW | |
| IOVANCE BIOTHERAPEUTICS INC | IOVA | $607.7K | 146,090 | - | new | NEW | |
| MACROGENICS INC | MGNX | $599.8K | 129,822 | +0.02pp | 2q | +224.6%+$415.0K | |
| GILEAD SCIENCES INC | GILD | $587.2K | 4,648 | -0.03pp | 3q | -26.8%-$215.2K | |
| NATERA INC | NTRA | $582.8K | 2,147 | flat | 3q | HELD | |
| SEAPORT THERAPEUTICS INC | SPTX | $564.7K | 26,000 | - | new | NEW | |
| ASSEMBLY BIOSCIENCES INC | ASMB | $561.9K | 20,447 | -0.01pp | 4q | +2.5%+$13.7K | |
| CYBIN INC | HELP | $537.2K | 81,278 | +0.02pp | 4q | +159.9%+$330.5K | |
| BENITEC BIOPHARMA INC | BNTC | $535.2K | 40,000 | +0.01pp | 2q | +128.6%+$301.1K | |
| POLYPID LTD | PYPD | $528.1K | 103,950 | flat | 3q | HELD | |
| PULMONX CORP | LUNG | $525.8K | 404,497 | flat | 5q | +8.0%+$39.0K | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $525.7K | 27,000 | -0.50pp | 2q | -94.1%-$8.4M | |
| GLOBA TERRA ACQUISITION COR | GTERU | $519.5K | 50,000 | -0.01pp | 4q | HELD | |
| TRAWS PHARMA INC | TRAW | $504.1K | 597,729 | +0.01pp | 3q | +287.9%+$374.1K | |
| WISDOMTREE TR | USFR | $503.5K | 10,000 | -0.01pp | 11q | HELD | |
| TECTONIC THERAPEUTIC INC | TECX | $498.5K | 14,501 | flat | 9q | +11.5%+$51.6K | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $480.6K | 895 | -0.01pp | 6q | HELD | |
| ARVINAS INC | ARVN | $478.6K | 57,591 | -0.01pp | 6q | HELD | |
| ORTHOPEDIATRICS CORP | KIDS | $478.2K | 25,000 | flat | 3q | +26.0%+$98.6K | |
| COGENT BIOSCIENCES INC | COGT | $472.1K | 12,200 | - | new | NEW | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $465.5K | 42,900 | -0.01pp | 8q | HELD | |
| MIRUM PHARMACEUTICALS INC | MIRM | $456.6K | 3,900 | -0.01pp | 2q | -37.1%-$269.3K | |
| KIORA PHARMACEUTICALS INC | KPRX | $441.7K | 167,941 | flat | 9q | HELD | |
| KURA ONCOLOGY INC | KURA | $438.8K | 40,000 | flat | 6q | HELD | |
| CONTEXT THERAPEUTICS INC | CNTX | $416.0K | 750,969 | -0.04pp | 10q | +113.9%+$221.5K | |
| ISHARES TR | STIP | $408.6K | 4,000 | - | new | NEW | |
| KALARIS THERAPEUTICS INC | KLRS | $407.0K | 100,000 | -0.02pp | 3q | HELD | |
| BICARA THERAPEUTICS INC | BCAX | $406.9K | 13,705 | flat | 5q | HELD | |
| MERCK & CO INC | MRK | $403.5K | 3,140 | flat | 5q | HELD | |
| NEUMORA THERAPEUTICS INC. | NMRA | $357.0K | 210,000 | +0.01pp | 3q | +534.4%+$300.7K | |
| IRHYTHM HOLDINGS INC | IRTC | $356.9K | 3,000 | - | new | NEW | |
| ACHIEVE LIFE SCIENCE INC | ACHV | $351.3K | 53,800 | +0.01pp | 10q | +12.6%+$39.2K | |
| ALIBABA GROUP HLDG LTD | BABA | $343.4K | 3,578 | -0.01pp | 4q | HELD | |
| WW INTL INC | WW | $340.4K | 21,300 | -0.03pp | 4q | -63.1%-$581.7K | |
| CNS PHARMACEUTICALS INC | CNSP | $334.6K | 70,000 | - | new | NEW | |
| CRESCENT BIOPHARMA INC. | CBIO | $328.9K | 18,275 | -0.04pp | 3q | -63.6%-$576.0K | |
| BOSTON SCIENTIFIC CORP | BSX | $320.1K | 7,500 | -0.02pp | 3q | -25.0%-$106.7K | |
| ALTIMMUNE INC | ALT | $312.6K | 102,823 | - | new | NEW | |
| VERASTEM INC | VSTM | $289.6K | 75,800 | -0.01pp | 2q | +6.6%+$18.0K | |
| AN2 THERAPEUTICS INC | ANTX | $284.6K | 58,808 | +0.01pp | 2q | +324.3%+$217.5K | |
| JOURNEY MED CORP | DERM | $279.8K | 39,517 | - | new | NEW | |
| PROCAP ACQUISITION CORP | PCAPU | $279.4K | 26,940 | flat | 5q | HELD | |
| PMV PHARMACEUTICALS INC | PMVP | $269.4K | 201,008 | flat | 10q | -13.0%-$40.2K | |
| COMPASS THERAPEUTICS INC | CMPX | $267.5K | 122,132 | -0.03pp | 5q | -12.1%-$36.9K | |
| JD.COM INC | JD | $254.8K | 10,000 | -0.01pp | 4q | HELD | |
| REZOLUTE INC | RZLT | $253.1K | 48,679 | flat | 9q | -17.0%-$52.0K | |
| ANAPTYSBIO INC | ANAB | $249.6K | 3,698 | flat | 2q | HELD | |
| NEUROGENE INC | NGNE | $245.3K | 7,800 | - | new | NEW | |
| ISHARES TR | IHI | $242.1K | 4,900 | - | new | NEW | |
| RXSIGHT INC | RXST | $241.0K | 50,000 | flat | 3q | +15.6%+$32.5K | |
| COYA THERAPEUTICS INC | COYA | $239.3K | 40,900 | flat | 2q | HELD | |
| BICYCLE THERAPEUTICS PLC | BCYC | $214.7K | 50,638 | -0.01pp | 2q | -29.0%-$87.6K | |
| CANTOR EQUITY PARTNERS VI IN | CEPS | $207.4K | 20,000 | flat | 2q | HELD | |
| SCYNEXIS INC | $201.0K | 49,387 | - | new | NEW | ||
| PERSONALIS INC | PSNL | $201.0K | 15,000 | flat | 2q | -40.0%-$134.0K | |
| Q/C TECHNOLOGIES INC | QCLS | $195.0K | 50,000 | flat | 2q | HELD | |
| CABALETTA BIO INC | CABA | $155.5K | 50,000 | - | new | NEW | |
| RECURSION PHARMACEUTICALS IN | RXRX | $150.5K | 41,000 | flat | 8q | +17.1%+$22.0K | |
| ORGANON & CO | OGN | $135.4K | 10,000 | flat | 10q | HELD | |
| MILESTONE PHARMACEUTICALS IN | MIST | $134.0K | 100,000 | flat | 3q | HELD | |
| NEUPHORIA THERAPEUTICS INC | NEUP | $131.1K | 30,000 | flat | 3q | HELD | |
| NEURONETICS INC | STIM | $130.0K | 100,000 | flat | 2q | HELD | |
| CHEMOMAB THERAPEUTICS LTD | CMMB | $129.6K | 80,000 | flat | 3q | HELD | |
| SOLIDION TECHNOLOGY INC OPT | STI | $125.4K | options only | flat | 4q | OPTIONS | |
| VOYAGER THERAPEUTICS INC | VYGR | $122.5K | 35,000 | flat | 11q | HELD | |
| ENTRADA THERAPEUTICS INC | TRDA | $114.1K | 15,500 | -0.02pp | 2q | -49.2%-$110.4K | |
| VERU INC | VERU | $109.5K | 35,000 | flat | 3q | HELD | |
| CANTOR EQUITY PARTNERS VII I | CAES | $100.9K | 10,000 | - | new | NEW | |
| CLENE INC | CLNN | $92.3K | 15,000 | - | new | NEW | |
| VISTAGEN THERAPEUTICS INC | VTGN | $79.4K | 351,141 | -0.02pp | 8q | -53.3%-$90.4K | |
| LONGEVERON INC | LGVN | $76.2K | 108,406 | -0.01pp | 2q | -45.8%-$64.4K | |
| BIOMEA FUSION INC | BMEA | $63.8K | 43,420 | flat | 3q | HELD | |
| LITE STRATEGY INC | LITS | $62.1K | 67,292 | flat | 4q | HELD | |
| JASPER THERAPEUTICS INC | JSPR | $58.9K | 140,000 | flat | 3q | HELD | |
| ARDELYX INC | ARDX | $56.1K | 11,000 | -0.01pp | 2q | -54.0%-$65.8K | |
| GOSSAMER BIO INC | GOSS | $35.0K | 212,531 | flat | 11q | -26.1%-$12.3K | |
| ATYR PHARMA INC | ATYR | $30.2K | 50,685 | flat | 5q | HELD | |
| A SPAC III ACQUISITION CORP | ASPCR | $19.1K | 215,000 | flat | 6q | HELD | |
| PROQR THRAPEUTICS N V | PRQR | $18.6K | 10,000 | flat | 7q | HELD | |
| BEST SPAC I ACQUISITION CORP | BSAAR | $16.6K | 100,000 | - | new | NEW | |
| COHERUS ONCOLOGY INC | CHRS | $14.5K | 10,366 | flat | 5q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.8B | 82.6% |
| Funds & ETFs | $115.1M | 5.3% |
| Medical Devices | $79.1M | 3.6% |
| Other sectors | $45.5M | 2.1% |
| Not classified | $139.7M | 6.4% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $2.2B | 272 | 44 | 94 | 64 | 71 | 42.0% | 45 |
| Q1 2026 | $1.7B | 299 | 73 | 96 | 56 | 30 | 40.6% | 48 |
| Q4 2025 | $1.4B | 256 | 81 | 77 | 47 | 28 | 45.2% | 49 |
| Q3 2025 | $1.1B | 203 | 49 | 66 | 53 | 49 | 51.3% | 45 |
| Q2 2025 | $652.1M | 203 | 44 | 59 | 53 | 39 | 50.6% | 45 |
| Q1 2025 | $538.7M | 198 | 47 | 67 | 39 | 55 | 44.1% | 45 |
| Q4 2024 | $500.4M | 206 | 48 | 54 | 68 | 104 | 49.4% | 44 |
| Q3 2024 | $614.9M | 262 | 91 | 74 | 71 | 79 | 53.5% | 45 |
| Q2 2024 | $529.7M | 250 | 63 | 84 | 44 | 60 | 60.6% | 44 |
| Q1 2024 | $440.8M | 247 | 124 | 35 | 44 | 36 | 62.2% | 45 |
| Q4 2023 | $279.8M | 159 | 0 | 0 | 0 | 0 | 62.7% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.